secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANI PHARMACEUTICALS INC (ANIP)
CIK:        0001023024
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000950103-24-011897
Event type: debt
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ANI Pharmaceuticals prices upsized $275M 2.25% convertible notes due 2029
-------------------------------------------------------------------------

- Aggregate principal $275M (upsized from $250M); net proceeds ~$266.8M (or ~$306.8M if full option exercised).
- Notes bear 2.25% interest semi-annually, mature Sept 1, 2029; initial conversion price ~$74.11/share, 30% premium.
- Proceeds: ~$35.3M for capped call transactions; remainder to repay existing senior secured term loan facility.
- Company plans new $325M delayed draw term loan and $75M revolving facility concurrently with closing.
- Initial purchasers have 13-day option to purchase additional $41.25M principal amount of notes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1023024/000095010324011897/0000950103-24-011897-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1023024/000095010324011897/dp216242_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-24-011897

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer